标题
Entinostat for treatment of solid tumors and hematologic malignancies
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 10, Pages 1455-1467
出版商
Informa Healthcare
发表日期
2011-09-03
DOI
10.1517/13543784.2011.613822
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC)
- (2017) R. A. Juergens et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Activation of the Estrogen Receptor- and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
- (2011) G. J. Sabnis et al. CANCER RESEARCH
- Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
- (2011) Steven A. Belinsky et al. CANCER RESEARCH
- HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells
- (2010) Choon-Kee Lee et al. CANCER LETTERS
- Histone deacetylase inhibitors in lymphoma
- (2010) Amanda Copeland et al. CURRENT OPINION IN ONCOLOGY
- Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275
- (2010) Annette Altmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Deacetylation of the DNA-binding Domain Regulates p53-mediated Apoptosis
- (2010) Hestia S. Mellert et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells
- (2010) Giovanni Di Bernardo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
- (2010) Jiahuai Tan et al. Journal of Hematology & Oncology
- Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition
- (2010) Masatoshi Kakihana et al. Journal of Thoracic Oncology
- MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo
- (2010) R. K. Srivastava et al. MOLECULAR CANCER THERAPEUTICS
- Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
- (2010) William Brazelle et al. PLoS One
- ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
- (2009) S. E. Witta et al. ANNALS OF ONCOLOGY
- HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines
- (2009) Sylwia Flis et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Rescue of Major Histocompatibility-DR Surface Expression in Retinoblastoma-Defective, Non-small Cell Lung Carcinoma Cells by the MS-275 Histone Deacetylase Inhibitor
- (2009) Melissa Ihla Niesen et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
- (2009) X. Huang et al. CANCER RESEARCH
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells
- (2009) Sylwia Flis et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL
- (2009) Dolly G. Aguilera et al. JOURNAL OF NEURO-ONCOLOGY
- Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
- (2009) Axel Hauschild et al. MELANOMA RESEARCH
- Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8
- (2009) S Häcker et al. ONCOGENE
- Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions
- (2009) Bérengère Vire et al. PLoS One
- DNER, an Epigenetically Modulated Gene, Regulates Glioblastoma-Derived Neurosphere Cell Differentiation and Tumor Propagation
- (2009) Peng Sun et al. STEM CELLS
- Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells
- (2009) Wei Qu et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours
- (2008) A Khandelwal et al. BRITISH JOURNAL OF CANCER
- Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
- (2008) Annie Hurtubise et al. Cancer Cell International
- Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
- (2008) Mareike Schmudde et al. CANCER LETTERS
- Sp1-Mediated TRAIL Induction in Chemosensitization
- (2008) J. Xu et al. CANCER RESEARCH
- Differential responsiveness of human hepatoma cellsversusnormal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics
- (2008) Johanna Dzieran et al. CANCER SCIENCE
- A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
- (2008) L. Gore et al. CLINICAL CANCER RESEARCH
- Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma
- (2008) C. L. Dalgard et al. CLINICAL CANCER RESEARCH
- Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
- (2008) Mari Björkman et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21 waf1 promoter in acute myelogenous leukemia cell
- (2008) C Nishioka et al. LEUKEMIA
- Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells
- (2008) C Nishioka et al. LEUKEMIA
- MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells
- (2008) Chie Nishioka et al. LEUKEMIA RESEARCH
- Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
- (2008) Shuzhen Liu et al. MOLECULAR CANCER THERAPEUTICS
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
- (2008) T. L.-A. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts
- (2007) Lalji K. Gediya et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells
- (2007) Shan Gao et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started